The Worldwide Market for Prescription Cardiovascular Drugs

 
   Single User - $3,500
   Hard Copy Mail Delivery - $3,500
   Corporate License - $7,000
   Online Download plus 1 Hard Copy - $3,800



Loading...
Published May 1, 2005 | 268 Pages | Pub ID: KLI1077786

The worldwide market for prescription cardiovascular drugs encompasses a wide variety of products that treat the many facets of cardiovascular disease. The field of cardiology is currently experiencing a busy and dynamic period. As a result, the range of therapeutic options available to physicians has expanded significantly in the past few years and the development pipeline promises even more weapons soon. The sheer size and diversity of the current market and the potential of new products make this therapeutic category among the most competitive of prescription drug segments.

This comprehensive market study considers the following market segments:

  • Cardiac glycosides and positive inotropic agents
  • Antihypertensive agents
  • Antiarrhythmic agents
  • Vasodilators and peripheral vasodilator agents
  • Antihyperlipidemic agents
  • Blood modifiers
  • Diuretic agents
  • Other cardiovascular agents

Specific diseases and disorders discussed include:

  • Angina
  • Arrhythmia
  • Atherosclerosis
  • Congestive heart failure
  • Coronary artery disease
  • Hypertension
  • Myocardial infarction
  • Other disorders

The report details the various categories of cardiovascular drugs and describes U.S. and non-U.S. markets in each of the specific cardiovascular drug areas. Revenues are considered in each subsegment according to type of drug. In addition, top products in each category are reviewed. The report also covers market drivers and trends that are influencing the market. It further identifies major market factors, which are discussed in detail, and a total market summary is presented.

All market data are presented at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2004. Historical data are provided for 2002 and 2003, and forecast data are provided for each of the years 2005 through 2009. Historical, base year, and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2004 base year.

The information and analysis presented in this report are based on extensive interviews with senior management of top companies and other participants in the cardiovascular market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 41 industry executives and product managers to validate and obtain expert opinion on current and future trends in the cardiovascular market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.

In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times